The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal

Ophthalmology

Volumn 110, Issue 7, 2003, Pages 1321-1326

  Mavrikakis, Ioannis ^a   Sfikakis, Petros P ^b   Mavrikakis, Emmanouil ^a   Rougas, Kostantinos ^a   Nikolaou, Athanasios ^c   Kostopoulos, Charalambos ^d   Mavrikakis, Myron ^a,d  

^a Ophthalmiatrion Athinon   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c ATHENS MEDICAL CENTER   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLOR VISION; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPHTHALMOLOGY; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULOPATHY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ACUITY; VISUAL FIELD;

EID: 0038154372     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00409-3     Document Type: Article

References (36)

1. Wallace DJ. Antimalarial therapies. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus, 4th ed. Philadelphia: Lea & Febiger, 1993; chap. 57:563-573.
2. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
3. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 1957;57:451-3.
4. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy, Lancet 1959;2:478-80.
5. Rynes RI. Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996;5 (Suppl. 1):573-4.
6. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.
7. Tobin DR, Krohel GB, Rynes RI. Hydroxychloroquine. Seven-year experience. Arch Ophthalmol 1982;100:81-3.
8. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1989; 30:1726-31.
9. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187-9.
10. Fraenkel L, Felson DT. Rheumatologists' attitudes toward routine screening for hydroxychloroquine retinopathy. J Rheumatol 2001;28:1218-21.
11. Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 1993;23:62-7.
12. Morsman CD, Livesey SJ, Richards IM, et al. Screening for hydroxychtoroquine retinal toxicity: is it necessary? Eye 1990; 4:572-6.
13. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-44.
14. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56: 188-90.
15. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40: 1482-6.
16. Spalton DJ. Retinopathy and antimalarial drugs - the British experience. Lupus 1996;5 (Suppl. 1):570-9.
17. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983;75:35-9.
18. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
19. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation, Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology, 2000.
20. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993;25: 385-8.
21. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 2000;27: 2703-6.
22. Warner AE. Early hydroxychloroquine macular toxicity. Arthritis Rheum 2001;44:1959-61.
23. Weiner A, Sandberg MA, Gaudio AR, et al. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;112:528-34.
24. Thorne JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. Br J Ophthalmol 1999;83: 1201-2.
25. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;75: 40-5.
26. Maturi RK, Folk JC, Nichols B, et al. Hydroxychloroquine retinopathy. Arch Ophthalmol 1999;117:1262-3.
27. Wei LC, Chen SN, Ho CL, et al. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J 2001;24:329-34.
28. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol 2002;133: 649-56.
29. Fielder A, Graham E, Jones S, et al. Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye 1998;12:907-9.
30. Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, 4th ed. Vol. 2. St. Louis: Mosby, 1997:776-8.
31. Kearns TP, Hollenhorst RW. Chloroquine retinopathy. Evaluation by fluorescein fundus angiography. Arch Ophthalmol 1966;76:378-84.
32. Cruess AF, Schachat AP, Nicholl J, et al. Chloroquine retinopathy. Is fluorescein angiography necessary? Ophthalmology 1985;92:1127-9.
33. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin 1999; 39:49-57.
34. Nozik RA, Weinstock FJ, Vignos PJ Jr. Ocular complications of chloroquine. Am J Ophthalmol 1964;58:774-8.
35. Okun E, Gouras P, Bernstein H, von Sallamann L. Chloroquine retinopathy: a report of eight cases with ERG and dark-adaptation findings. Arch Ophthalmol 1963;6:59-71.
36. Heijl A, Lindgren G, Olsson J. Normal variability of static perimetric threshold values across the central visual field. Arch Ophthalmol 1987;105:1544-9.